Bp Plc cut its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 5.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 191,000 shares of the biopharmaceutical company’s stock after selling 12,000 shares during the quarter. Bp Plc’s holdings in Bristol-Myers Squibb were worth $10,643,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Cliftonlarsonallen Wealth Advisors LLC increased its stake in Bristol-Myers Squibb by 4.6% in the second quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 22,776 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 1,000 shares during the period. Advisor Partners LLC increased its stake in Bristol-Myers Squibb by 5.8% in the second quarter. Advisor Partners LLC now owns 34,579 shares of the biopharmaceutical company’s stock valued at $1,927,000 after purchasing an additional 1,891 shares during the period. Alley Co LLC increased its stake in Bristol-Myers Squibb by 1.8% in the second quarter. Alley Co LLC now owns 86,453 shares of the biopharmaceutical company’s stock valued at $4,817,000 after purchasing an additional 1,557 shares during the period. Pictet Asset Management Ltd. increased its stake in Bristol-Myers Squibb by 1.1% in the second quarter. Pictet Asset Management Ltd. now owns 1,791,291 shares of the biopharmaceutical company’s stock valued at $96,641,000 after purchasing an additional 20,159 shares during the period. Finally, Goelzer Investment Management Inc. increased its stake in Bristol-Myers Squibb by 0.8% in the second quarter. Goelzer Investment Management Inc. now owns 76,002 shares of the biopharmaceutical company’s stock valued at $4,235,000 after purchasing an additional 600 shares during the period. Institutional investors own 68.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bp Plc Sells 12,000 Shares of Bristol-Myers Squibb Company (BMY)” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2017/10/18/bp-plc-sells-12000-shares-of-bristol-myers-squibb-company-bmy.html.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 64.18 on Wednesday. The stock has a market cap of $105.25 billion, a P/E ratio of 23.44 and a beta of 1.19. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The company’s 50-day moving average is $62.78 and its 200-day moving average is $56.98.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $0.69 EPS. On average, analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.43%. Bristol-Myers Squibb’s payout ratio is 56.73%.

Several analysts have recently weighed in on the stock. Jefferies Group LLC downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a report on Monday. Barclays PLC lifted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a report on Monday, October 9th. Finally, UBS AG reaffirmed a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $63.21.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.